SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )
China Pharma Holdings, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
-------------------------------------------------------------------------------
(Title of Class of Securities)
16941T104
-------------------------------------------------------------------------------
(CUSIP Number)
May 30, 2008
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
----------
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 16941T104
---------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Peter Siris
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [x]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5. SOLE VOTING POWER
12,000
6. SHARED VOTING POWER
2,650,551
7. SOLE DISPOSITIVE POWER
12,000
8. SHARED DISPOSITIVE POWER
2,650,551
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,662,551
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.05%
12. TYPE OF REPORTING PERSON
IN
CUSIP No. 16941T104
---------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Guerrilla Capital Management, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [x]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5. SOLE VOTING POWER
0
6. SHARED VOTING POWER
2,650,551
7. SOLE DISPOSITIVE POWER
0
8. SHARED DISPOSITIVE POWER
2,650,551
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,650,551
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.02%
12. TYPE OF REPORTING PERSON
OO
CUSIP No. 16941T104
---------------------
Item 1(a). Name of Issuer:
China Pharma Holdings, Inc.
-------------------------------------------------------------------
Item 1(b). Address of Issuer's Principal Executive Offices:
2nd Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China
-------------------------------------------------------------------
Item 2(a). Name of Persons Filing:
Peter Siris
Guerrilla Capital Management, LLC
-------------------------------------------------------------------
Item 2(b). Address of Principal Business Office, or if None, Residence:
237 Park Avenue
9th Floor
New York, New York 10017
-------------------------------------------------------------------
Item 2(c). Citizenship:
Peter Siris - United States
Guerrilla Capital Management, LLC - Delaware
-------------------------------------------------------------------
Item 2(d). Title of Class of Securities:
Common Stock, $.001 par value
-------------------------------------------------------------------
Item 2(e). CUSIP Number:
16941T104
-------------------------------------------------------------------
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)
or (c), Check Whether the Person Filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Exchange Act.
(b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange
Act.
(d) [_] Investment company registered under Section 8 of the Investment
Company Act.
(e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act;
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act;
(j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
Peter Siris - 2,662,551
Guerrilla Capital Management, LLC 2,650,551
-------------------------------------------------------------------
(b) Percent of class:
Peter Siris - 7.05%
Guerrilla Capital Management, LLC 7.02%
-------------------------------------------------------------------
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
Peter Siris - 12,000
Guerrilla Capital Management, LLC 0
(ii) Shared power to vote or to direct the vote:
Peter Siris 2,650,551
Guerrilla Capital Management, LLC 2,650,551
(iii) Sole power to dispose or to direct the
disposition of:
Peter Siris 12,000
Guerrilla Capital Management, LLC 0
(iv) Shared power to dispose or to direct the
disposition of
Peter Siris 2,650,551
Guerrilla Capital Management, LLC 2,650,551
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities check the following [ ].
------------------------------------------------------------------------
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
N/A
-------------------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.
N/A
-------------------------------------------------------------------
Item 8. Identification and Classification of Members of the Group.
N/A
-------------------------------------------------------------------
Item 9. Notice of Dissolution of Group.
N/A
-------------------------------------------------------------------
Item 10. Certifications.
By signing below, the reporting persons certify that, to the best of its
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
/s/ Peter Siris*
-------------------
GUERRILLA CAPITAL MANAGEMENT, LLC*
By: /s/ Peter Siris
----------------------------------------
Name: Peter Siris
Title: Principal
Date: June 9, 2008
*The Reporting Persons disclaim beneficial ownership in the common stock
reported herein except to the extent of their pecuniary interest therein.
EXHIBIT A
AGREEMENT
The undersigned agree that this Schedule 13G dated June 9, 2008 relating to the
Common Stock, $.001 par value of China Pharma Holdings, Inc. shall be filed on
behalf of the undersigned.
/s/ Peter Siris*
-------------------
GUERRILLA CAPITAL MANAGEMENT, LLC
/s/ Peter Siris
___________________
By: Peter Siris
Title: Managing Member
Date: June 9, 2008
SK 02550 0001 890294